Ring-Substituted 1-Hydroxynaphthalene-2-Carboxanilides Inhibit Proliferation and Trigger Mitochondria-Mediated Apoptosis
暂无分享,去创建一个
K. Souček | T. Syrovets | J. Jampílek | R. Fedr | T. Goněc | P. Kollar | T. Kauerová | Susanne Hafner | A. Gaiser | S. Hafner | Tereza Kauerová
[1] R. Enriz,et al. Searching new structural scaffolds for BRAF inhibitors. An integrative study using theoretical and experimental techniques. , 2019, Bioorganic chemistry.
[2] A. Bąk,et al. Design and synthesis of anticancer 1-hydroxynaphthalene-2-carboxanilides with a p53 independent mechanism of action , 2019, Scientific Reports.
[3] Hsu-Shan Huang,et al. A new niclosamide derivatives‐B17 can inhibit urological cancers growth through apoptosis‐related pathway , 2018, Cancer medicine.
[4] R. Musioł. An overview of quinoline as a privileged scaffold in cancer drug discovery , 2017, Expert opinion on drug discovery.
[5] Yanli Jin,et al. The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma in vitro and in vivo , 2017, Theranostics.
[6] Sen Chen,et al. Niclosamide suppresses renal cell carcinoma by inhibiting Wnt/β-catenin and inducing mitochondrial dysfunctions , 2016, SpringerPlus.
[7] Š. Pospíšilová,et al. N-Alkoxyphenylhydroxynaphthalenecarboxamides and Their Antimycobacterial Activity , 2016, Molecules.
[8] J. Jampílek,et al. Antiproliferative and Pro-Apoptotic Effect of Novel Nitro-Substituted Hydroxynaphthanilides on Human Cancer Cell Lines , 2016, International journal of molecular sciences.
[9] S. Koenig,et al. The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway. , 2016, The Journal of surgical research.
[10] Y. Assaraf,et al. Repositioning of drugs for intervention in tumor progression and metastasis: Old drugs for new targets. , 2016, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[11] Hua Gao,et al. Synthesis of p‐O‐Alkyl Salicylanilide Derivatives as Novel EGFR Inhibitors , 2016, Drug development research.
[12] Mark A Feitelson,et al. Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. , 2015, Seminars in cancer biology.
[13] J. Férriz,et al. Salicylanilide carbamates: Promising antibacterial agents with high in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA). , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[14] X. Ren,et al. Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure. , 2015, Bioorganic & medicinal chemistry.
[15] M. Clausen,et al. FDA-approved small-molecule kinase inhibitors. , 2015, Trends in pharmacological sciences.
[16] A. Coffey,et al. Synthesis and Biological Evaluation of N-Alkoxyphenyl-3-hydroxynaphthalene-2-carboxanilides , 2015, Molecules.
[17] Javier León,et al. Myc and cell cycle control. , 2015, Biochimica et biophysica acta.
[18] I. Kushkevych,et al. Synthesis and antimycobacterial properties of ring-substituted 6-hydroxynaphthalene-2-carboxanilides. , 2015, Bioorganic & medicinal chemistry.
[19] R. Roskoski,et al. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. , 2015, Pharmacological research.
[20] Patrycja Nowak-Sliwinska,et al. The chicken chorioallantoic membrane model in biology, medicine and bioengineering , 2014, Angiogenesis.
[21] Donald J Buchsbaum,et al. Multi-targeted therapy of cancer by niclosamide: A new application for an old drug. , 2014, Cancer letters.
[22] Yuquan Wei,et al. The Anthelmintic Drug Niclosamide Induces Apoptosis, Impairs Metastasis and Reduces Immunosuppressive Cells in Breast Cancer Model , 2014, PloS one.
[23] J. Jampílek,et al. Antimycobacterial and herbicidal activity of ring-substituted 1-hydroxynaphthalene-2-carboxanilides. , 2013, Bioorganic & medicinal chemistry.
[24] W. Curran,et al. Inhibition of STAT3 by Niclosamide Synergizes with Erlotinib against Head and Neck Cancer , 2013, PloS one.
[25] R. Fimmers,et al. Anticancer Effects of Niclosamide in Human Glioblastoma , 2013, Clinical Cancer Research.
[26] A. Coffey,et al. Antibacterial and Herbicidal Activity of Ring-Substituted 2-Hydroxynaphthalene-1-carboxanilides , 2013, Molecules.
[27] A. Coffey,et al. Antibacterial and Herbicidal Activity of Ring-Substituted 2-Hydroxynaphthalene-1-carboxanilides , 2013, Molecules.
[28] Q. Shen,et al. Discovery of O-Alkylamino Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents. , 2013, ACS medicinal chemistry letters.
[29] V. Buchta,et al. In vitro antibacterial and antifungal activity of salicylanilide pyrazine-2-carboxylates. , 2012, Medicinal chemistry (Shariqah (United Arab Emirates)).
[30] Hans Clevers,et al. Wnt/β-Catenin Signaling and Disease , 2012, Cell.
[31] N. Sonenberg,et al. Structure-Activity Analysis of Niclosamide Reveals Potential Role for Cytoplasmic pH in Control of Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling* , 2012, The Journal of Biological Chemistry.
[32] F. Dick,et al. The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle , 2012, Cell Division.
[33] G. Piazza,et al. Niclosamide Suppresses Cancer Cell Growth By Inducing Wnt Co-Receptor LRP6 Degradation and Inhibiting the Wnt/β-Catenin Pathway , 2011, PloS one.
[34] M. Krátký,et al. Salicylanilide ester prodrugs as potential antimicrobial agents--a review. , 2011, Current pharmaceutical design.
[35] F. Khanim,et al. Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production , 2011, Blood cancer journal.
[36] A. Imramovský,et al. Salicylanilides and Their Derivatives as Perspective Antituberculosis Drugs: Synthetic Routes and Biological Evaluations , 2011 .
[37] P. Beroza,et al. Discovery and structure-activity relationships of modified salicylanilides as cell permeable inhibitors of poly(ADP-ribose) glycohydrolase (PARG). , 2011, Journal of medicinal chemistry.
[38] J. Hwang,et al. Niclosamide induces mitochondria fragmentation and promotes both apoptotic and autophagic cell death. , 2011, BMB reports.
[39] A. Imramovský,et al. Salicylanilides and Their Derivates as Perspective Anti-tuberculosis Drugs: Synthetic Routes and Biological Evaluations , 2011 .
[40] A. Hampl,et al. Geranylated flavanone tomentodiplacone B inhibits proliferation of human monocytic leukaemia (THP‐1) cells , 2011, British journal of pharmacology.
[41] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[42] Qiang He,et al. Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. , 2010, ACS medicinal chemistry letters.
[43] J. Dancey. mTOR signaling and drug development in cancer , 2010, Nature Reviews Clinical Oncology.
[44] Yanli Jin,et al. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. , 2010, Cancer research.
[45] X. Ren,et al. The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. , 2009, Biochemistry.
[46] M. Barbacid,et al. Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.
[47] J. Turkson,et al. STAT3 as a target for inducing apoptosis in solid and hematological tumors , 2008, Cell Research.
[48] Qiu-Ju Jiang,et al. Anion-triggered substituent-dependent conformational switching of salicylanilides. New hints for understanding the inhibitory mechanism of salicylanilides. , 2007, The Journal of organic chemistry.
[49] Elisa Nemes,et al. Multiparametric analysis of cells with different mitochondrial membrane potential during apoptosis by polychromatic flow cytometry , 2007, Nature Protocols.
[50] A. Giordano,et al. RB and cell cycle progression , 2006, Oncogene.
[51] E. Haura. SRC and STAT pathways. , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[52] W. Gerald,et al. Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. , 2006, Cancer research.
[53] Dajun Yang,et al. SUCI02 inhibits the erbB‐2 tyrosine kinase receptor signaling pathway and arrests the cell cycle in G1 phase in breast cancer cells , 2006, Cancer science.
[54] Arnaud M. Vigneron,et al. The STAT3 Transcription Factor Is a Target for the Myc and Riboblastoma Proteins on the Cdc25A Promoter* , 2005, Journal of Biological Chemistry.
[55] P. Furet,et al. Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor. , 2004, European journal of medicinal chemistry.
[56] Hua Yu,et al. The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.
[57] C. Thompson,et al. Mitochondrial membrane potential regulates matrix configuration and cytochrome c release during apoptosis , 2003, Cell Death and Differentiation.
[58] J. Pietenpol,et al. Cell-cycle dysregulation and anticancer therapy. , 2003, Trends in pharmacological sciences.
[59] J. Kuneš,et al. Relationship between the Structure and Antimycobacterial Activity of Substituted Salicylanilides , 2003, Archiv der Pharmazie.
[60] Y. Urano,et al. Development of Novel Fluorescence Probes That Can Reliably Detect Reactive Oxygen Species and Distinguish Specific Species* 210 , 2003, The Journal of Biological Chemistry.
[61] D. Ferrari,et al. Activation and caspase-mediated inhibition of PARP: a molecular switch between fibroblast necrosis and apoptosis in death receptor signaling. , 2002, Molecular biology of the cell.
[62] Martin Schuler,et al. Cytochrome C Maintains Mitochondrial Transmembrane Potential and Atp Generation after Outer Mitochondrial Membrane Permeabilization during the Apoptotic Process , 2001, The Journal of cell biology.
[63] G. Swan. The pharmacology of halogenated salicylanilides and their anthelmintic use in animals. , 1999, Journal of the South African Veterinary Association.
[64] R. Kanojia,et al. Substituted salicylanilides as inhibitors of two-component regulatory systems in bacteria. , 1998, Journal of medicinal chemistry.
[65] R. Benz,et al. The molecular mechanism of action of the proton ionophore FCCP (carbonylcyanide p-trifluoromethoxyphenylhydrazone). , 1983, Biophysical journal.
[66] R. Metcalf,et al. Salicylanilides: A New Group of Active Uncouplers of Oxidative Phosphorylation , 1967, Science.
[67] G. C. Walker,et al. Antifungal action of salicylanilide. II. , 1960, Canadian journal of biochemistry and physiology.
[68] D. Karnofsky,et al. Growth of transplantable human tumors in the chick embryo and hatched chick. , 1956, Cancer research.
[69] R. Pathak,et al. The chick chorioallantoic membrane (CAM) as a versatile patient-derived xenograft (PDX) platform for precision medicine and preclinical research. , 2018, American journal of cancer research.
[70] J. Trapani,et al. Assaying cytochrome C translocation during apoptosis. , 2004, Methods in molecular biology.
[71] H. Wolf‐Watz,et al. Salicylanilides are potent inhibitors of type III secretion in Yersinia. , 2003, Advances in experimental medicine and biology.